Table 3.
CMR-Based Change in Diagnosis
| Post-CMR diagnosis | All patients (n = 208) | All patients Change in diagnosis | Primary prevention (n = 115) | Primary prevention Change in diagnosis | Secondary prevention (n = 93) | Secondary prevention Change in diagnosis |
|---|---|---|---|---|---|---|
| Acute MI | 2 | 2 (1) | 1 | 1 (1) | 1 | 1 (1) |
| Cardiac storage disease | 1 | 0 (0) | 1 | 0 (0) | 0 | 0 (0) |
| ARVC | 5 | 3 (1) | 1 | 0 (0) | 4 | 3 (3) |
| Idiopathic DCM | 43 | 13 (6) | 33 | 9 (8) | 10 | 4 (4) |
| HCM | 7 | 2 (1) | 3 | 1 (1) | 4 | 1 (1) |
| HHD | 25 | 22 (11) | 11 | 11 (10) | 14 | 11 (12) |
| ICM | 63 | 8 (4) | 40 | 2 (2) | 23 | 6 (6) |
| NCCM | 1 | 1 (0.5) | 0 | 0 (0) | 1 | 1 (1) |
| Normal (prior LGE (+) VT ablation lesions) | 4 | 4 (2) | 1 | 1 (1) | 3 | 3 (3) |
| Normal | 21 | 10 (5) | 5 | 4 (3) | 16 | 6 (6) |
| Post–acute myocarditis | 20 | 13 (6) | 9 | 5 (4) | 11 | 8 (9) |
| PPCM | 2 | 0 (0) | 2 | 0 (0) | 0 | 0 (0) |
| Cardiac sarcoidosis | 7 | 4 (2) | 4 | 2 (2) | 3 | 2 (2) |
| Systemic sclerosis | 1 | 0 (0) | 0 | 0 (0) | 1 | 0 (0) |
| TOF | 1 | 0 (0) | 0 | 0 (0) | 1 | 0 (0) |
| VHD | 5 | 1 (0.5) | 4 | 1 (1) | 1 | 0 (0) |
| Total | 208 | 83 (40) | 115 | 37 (32) | 93 | 46 (49)* |
Values are n (%) for all, primary and secondary prevention groups. MI myocardial infarction; ARVC arrhythmogenic right-ventricular cardiomyopathy; DCM dilative cardiomyopathy; HCM hypertrophic cardiomyopathy; HHD hypertensive heart disease; ICM ischemic cardiomyopathy; NCCM non-compaction cardiomyopathy; LGE late gadolinium enhancement; VT ventricular tachycardia; PPCM peripartum cardiomyopathy; TOF tetralogy of Fallot; VHD valvular heart disease. * p = 0.011 for the comparison of primary versus secondary prevention